IONS · Ionis Pharmaceuticals, Inc.
AI read · Neutral
The AI's read
A share target is one firm's estimate, not a change to Ionis's sales or medicines. Keeping its favorable rating softens the cut, and the report gives no new company results.
Barclays has cut its price target for Ionis Pharmaceuticals to $70 from $85 but still thinks the stock is a good buy.
Neutral
Barclays lowered its share target from $85 to $70 but kept its favorable rating. These mixed analyst views do not show a clear change in Ionis's business outlook.
Get alerts for IONS
Follow Ionis Pharmaceuticals, Inc. (IONS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IONSFree on the App Store and Google Play, or on the web.